Biogen reported more positive numbers for the firm’s biosimilars business in the first quarter of this year, although some of this growth was attributed to “accelerated sales” stemming from the COVID-19 pandemic. Meanwhile, the company revealed its latest thinking as it continues attempts to shield its key Tecfidera brand from competition in the US, following a fresh unfavorable patent ruling.
Sales of Imraldi (adalimumab) jumping by three-quarters after more than a year on the market allowed Biogen to report overall biosimilars sales that jumped by 25% to $219m in the first three months of this year, albeit with a non-recurring bump stemming from the COVID-19 pandemic.
Approximately 75,000 patients in Europe are now being treated with the biosimilar to AbbVie’s Humira, developed by Samsung Bioepis...
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
